10:19 AM EDT, 03/25/2024 (MT Newswires) -- Cassava Sciences ( SAVA ) on Monday announced the completion of another interim safety review of its drug candidate simufilam in ongoing Phase 3 clinical trials involving Alzheimer's disease patients.

An independent data and safety monitoring board recommended continuing the phase 3 clinical trials of simufilam in patients with Alzheimer's disease as planned.

Cassava Sciences' ( SAVA ) simufilam, a drug candidate for Alzheimer's disease dementia, is in late-stage Phase 3 trials with over 1,900 enrolled patients.

The first Phase 3 trial has a 52-week treatment period, with top-line results expected around year-end 2024. The second Phase 3 trial has a 76-week treatment period, with top-line results expected around mid-year 2025, the company said.

Shares of Cassava Sciences ( SAVA ) were up 3.8% in recent Monday trading.

Price: 20.56, Change: +0.75, Percent Change: +3.79